Sasaki et al. documented the upregulation of the tlr4 gene in both Huh7 and HepG2 cells upon treatment with lenvatinib, while the tlr4 gene was downregulated in Huh7 cells upon regorafenib treatment, comprising indirect evidence that TLR4 signaling might be implicated in the regulation of drug resistance in HCC [83]. Here, TLR4 is linked to hepatocellular carcinoma.